Search Results

According to Latest Study, the Europe active pharmaceutical ingredients (API) market size was estimated at USD 45.43 billion in 2023 and it is expected to grow at a CAGR of 5.78% from 2024 to 2033, to reach around USD 79.69 billion by 2033.

PurMinds NeuroPharma (“PurMinds” or the “Company”), a neuro-medicine development company focused on advancing novel therapeutics for neurological and neurodegenerative disorders, today announced that it has signed the first Controlled Substances Supply Agreement with Bluestem API Inc (“Bluestem”) to produce and supply botanical psilocybin from its Ontario based neurolab and production facility that holds a Dealer’s License for Controlled Drugs and Substances (“DL”).

Asymchem Laboratories Co., Ltd. announced that it will operate the former Pfizer U.K. small molecule API pilot plant and part of the development laboratories through a new lease agreement between Asymchem and Discovery Park, establishing Asymchem’s first manufacturing footprint in Europe.

According to a new report by nova one advisor, the U.S. active pharmaceutical ingredient (API) market size was valued at USD 37.19 billion in 2023 and is anticipated to reach around USD 72.21 billion by 2033, growing at a CAGR of 6.86% from 2024 to 2033.